Overview

OPALINE : A Study Of Morbidity And Mortality At 2 Years

Status:
Completed
Trial end date:
2019-11-18
Target enrollment:
Participant gender:
Summary
A descriptive, prospective (partly retrospective), multisite, observational study conducted in France in adult patients treated for a well differentiated, unresectable or metastatic, pancreatic neuroendocrine tumor with disease progression.
Details
Lead Sponsor:
Pfizer
Collaborators:
Keyrus
Keyrus Biopharma
Novartis
Treatments:
Everolimus
Sirolimus
Sunitinib